Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
| Autor: | F. Calisti, I. Costamagna, J. Hsu, M. Tocco, A. Pikalov, R. Goldman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | European Psychiatry, Vol 64, Pp S166-S166 (2021) |
| Druh dokumentu: | article |
| ISSN: | 0924-9338 1778-3585 |
| DOI: | 10.1192/j.eurpsy.2021.442 |
| Popis: | Introduction Onset of schizophrenia commonly occurs during late adolescence or early adulthood and is often characterized by greater symptom severity and impairment. Objectives To evaluate the efficacy and safety of lurasidone in the treatment of acute schizophrenia in adolescents and young adults. Methods The 4 studies in this pooled analysis used similar study designs. Patients (ages 13-25 years) were randomized to 6 weeks of double-blind, placebo-controlled treatment with once-daily lurasidone (37 mg, 74 mg, 111 mg, 148 mg). The primary outcome was endpoint change in the Positive and Negative Syndrome Scale (PANSS) total score; secondary measures included the Clinical Global Impression, Severity scale (CGI-S). Results The safety population consisted of 537 patients; 79.1% completed the studies. Treatment with lurasidone was significant (P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|